Fibralign Corporation is an advanced biomedical devices company.
Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices.
Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development for new applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 18, 2012 | Grant | $179.96K | 1 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Grant |